The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...

With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its ...

With a positive classification from the DEA paving the way for Orzeyful’s U.S. launch on Thursday, Takeda is charting new ...

Following the blue tidal wave in the midterms that restored Democrats to power in both chambers of Congress, lawmakers on the ...

New research out from Mount Sinai has found that a dozen AI models it tested from major tech companies were more likely to ...

In a series of regulatory wrist-slaps now made public, the FDA has taken three manufacturers to task over record request ...

Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, ...

Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...

Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar ...

ImmuniyBio is eyeing a move up the non-muscle invasive bladder cancer (NMIBC) treatment line for its immunotherapy Anktiva. ...

Vertex has decided to lay off 78 employees at Crinetics Pharmaceuticals following its $10 billion acquisition of the ...

Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...